Roger Dansey, M.D. is the President, Research and Development of Seagen, a global biotechnology company focusing on transformative cancer medicines. Previously, Dr.  Dansey was Senior Vice President at Merck Inc., where he led the company’s late-stage oncology development efforts.  Earlier in his career, he lead oncology clinical research at Gilead Sciences and had multiple oncology and hematology roles at Amgen.  At Seagen, Dr. Dansey has used his extensive drug development experience to quickly move the company from a single product US-based company to a four product company with a European Commercial and Development presence.  Dr. Dansey has overseen all aspects of the clinical development of the initial regulatory approvals of PADCEV, TUKYSA, and TIVDAK, as well as supplemental approvals for ADCETRIS, PADCEV, and TUKYSA.  Dr. Dansey also oversees the Translational Sciences group as well as an extensive early development pipeline of programs that are in the clinic. Dr. Dansey served as interim CEO at Seagen from May 2022 to November 2022 during a challenging time for Seagen after the former CEO left the company. Dr. Dansey also currently serves on the Board of Directors of Inovio Pharmaceuticals.